Astellas, Daiichi Move Ahead With Factor Xa Programs
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese pharmas, each in Phase IIb with their oral Factor Xa inhibitors, are behind J&J/Bayer and Bristol/Pfizer, which have Phase III candidates.
You may also be interested in...
Theravance/Astellas Antibiotic Telavancin “Approvable” At FDA
Complete response to agency will not require additional trials, but may include revising label, re-analysis of data, Theravance CEO says.
FDA Advisory Committee Meeting Planned To Review Atrial Fibrillation Drugs
Safety and efficacy of Cardiome/Astellas’ vernakalant and Solvay’s tedisamil will be debated during the Dec. 11-12 meeting, according to Cardiome.
Daiichi Sankyo U.S. CEO Joe Pieroni: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Exec discusses the anti-platelet drug prasugrel that Daiichi is developing with Lilly, Daiichi’s planned sales force expansion, and his views on partnering in the U.S. and Asia.